ALK-Abelló announces positive third year results from clinical study with GRAZAX®

Summary: ALK-Abelló announces highly significant and positive third year
results from clinical study with GRAZAX® which support expectations of a
long-term disease-modifying effect of the therapy. 

Today, ALK-Abelló announces positive results from the third treatment year of
the GT-08 study with GRAZAX®, the company's tablet-based vaccine against grass
pollen allergy. The study documents that the highly significant clinical effect
from the first and second years of treatment is sustained through the third
year and even increases when taking into account the differences between the
three pollen seasons. Furthermore, an increasing, positive effect on the immune
system is documented. 

In the third treatment year, GRAZAX® significantly reduces hay fever symptoms
and the use of symptom relieving-medication (p<0.001). Hay fever symptoms are
reduced by 37% while the use of symptom-relieving medication is reduced by 60%.
The reduction of symptoms and use of medication is measured as median values
relative to a placebo group in which patients had unrestricted access to
symptom-relieving medication. Thus, the effect of GRAZAX® comes in addition to
the effect from placebo and symptom-relieving medication. 

Following the three-year treatment period, a further efficacy analysis has been
made taking into account the differences between the three pollen seasons. This
analysis documents that the clinical effect increases significantly over the
three years of treatment. 

In addition, blood samples from patients show a significant, increasing effect
on the immune system indicating an increasing tolerance to grass pollen. These
findings emphasize that treatment with GRAZAX® has a modifying effect on the
underlying allergic disease. 

The tolerability profile was gradually improved during the three years of daily
treatment, and the product was also well tolerated by patients in the third
year of treatment. 

The results support ALK-Abelló's expectations that GRAZAX® will have a lasting,
significant effect when the recommended three-year treatment period ends. Such
a lasting effect cannot be obtained with traditional symptom-relieving allergy
medication. In order to finally document this effect, the study will now be
concluded by a two-year follow-up period in which patients no longer receive
active treatment with GRAZAX®. 

GRAZAX® is the first allergy tablet that treats the underlying cause of grass
pollen allergy as well as the allergy symptoms. 

Hørsholm, March 1, 2008


ALK-Abelló A/S

Jens Bager
President and CEO

For further information, please contact:
Jens Bager, President and CEO, telephone +45 4574 7576
Per Plotnikof, Investor Relations, telephone +45 2261 2525
Jacob Frische, Group Communications, telephone +45 2224 7551